Bionano Genomics (BNGO) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
3 Feb, 2026Opening remarks and agenda
Meeting opened by the President and CEO, with introductions of board members and executive team, and acknowledgment of virtual attendance.
Transition of Board Chairman from David Barker to Al Luderer, in line with governance plans.
Auditors and legal counsel present to respond to questions; meeting agenda and rules of conduct outlined.
Board and executive committee updates
Al Luderer appointed as new Chairman, recognized for his long-standing board service and industry experience.
David Barker thanked for his years as Chairman and will continue as a board member.
Corporate governance
Inspector of Election appointed and sworn in to oversee voting process.
Quorum established with 44.94% of outstanding shares represented.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Bionano Genomics
- 2025 saw revenue of $28.5M, margin gains, and a 2026 outlook for $30–$33M growth.BNGO
Q4 202523 Mar 2026 - Q2 revenue dropped 10% to $7.8M; OGM installs up 29%, but liquidity risks persist.BNGO
Q2 20242 Feb 2026 - Stratys adoption accelerates as new CPT code and workflow advances drive clinical and market growth.BNGO
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Shifting to a capital-efficient, recurring revenue model with streamlined operations and focused growth.BNGO
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - Revenue down 35%, OGM and flowcell sales up, but urgent funding needed for ongoing operations.BNGO
Q3 202414 Jan 2026 - Share issuance and reverse stock split proposals both approved by stockholders.BNGO
EGM 202510 Jan 2026 - Q4 revenue down 24% but gross margin up; 2025 revenue guided at $29M–$32M.BNGO
Q4 202426 Dec 2025 - Registering 35M+ shares for resale amid ongoing losses and cash constraints, with Nasdaq risks.BNGO
Registration Filing16 Dec 2025 - Registration enables resale of 12.25M shares by investors; company receives no proceeds.BNGO
Registration Filing16 Dec 2025